🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Isabel Arrillaga‐Romany

Massachusetts General Hospital

ORCID: 0000-0001-5951-1225

Also affiliated with Center for Neuro-Oncology

MathematicsMedicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile
0Author DataRank

Indexed papers

0in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 11 papers. Top paper: “The landscape of tumor cell states and spatial organization in H3-K27M mutant diffuse midline glioma across age and location”.

The landscape of tumor cell states and spatial organization in H3-K27M mutant diffuse midline glioma across age and location

Nature Genetics(2022)10.1038/s41588-022-01236-3
N/A
0.793DataRank · unranked
197 citations

Li Jiang, Erik Samuelsson, Sergio Marco Salas, Alexander Beck, Olivia A. Hack +41 more

Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways

Cancer Discovery(2023)10.1158/2159-8290.cd-23-0131
N/A
0.757DataRank · unranked
155 citations

Abed Rahman Kawakibi, Sunjong Ji, Sebastian M. Waszak, Stefan R. Sweha, Mateus Mota +79 more

Neoadjuvant anti-PD1 immunotherapy for surgically accessible recurrent glioblastoma: clinical and molecular outcomes of a stage 2 single-arm expansion cohort

Nature Communications(2024)10.1038/s41467-024-54326-7
N/A
0.730DataRank · unranked
37 citations

Lu Sun, Gilbert C. Youssef, Raymond Y. Huang, Gang Li, Jiyoon Kim +31 more

Myo-Inositol Levels Measured with MR Spectroscopy Can Help Predict Failure of Antiangiogenic Treatment in Recurrent Glioblastoma

Radiology(2021)10.1148/radiol.2021210826
N/A
0.666DataRank · unranked
17 citations

Michael Wenke, Pratik Talati, Melanie Fu, Daniel Kim, Akila Weerasekera +15 more

Mutant IDH inhibitors induce lineage differentiation in IDH-mutant oligodendroglioma

Cancer Cell(2024)10.1016/j.ccell.2024.03.008
N/A
0.614DataRank · unranked
59 citations

Simon Gritsch, Masashi Nomura, Alexander Jucht, Jérôme Fortin, Ramya Raviram +25 more

Correcting the drug development paradigm for glioblastoma requires serial tissue sampling

Nature Medicine(2023)10.1038/s41591-023-02464-8
N/A
0.604DataRank · unranked
55 citations

Kelly Hotchkiss, Ian F. Parney, John de Groot, Solmaz Sahebjam, Nader Sanai +31 more

Prognostic significance of O6-methylguanine-DNA methyltransferase promoter methylation status in isocitrate dehydrogenase-mutant glioma

Neuro-Oncology(2025)10.1093/neuonc/noaf287
N/A
0.241DataRank · unranked
4 citations

Elisa Aquilanti, Julie J. Miller, Zhou Lan, Aleksandra B Lasica, Isabel Arrillaga‐Romany +20 more

IDH-mutant glioma: A new IDH1 inhibitor moves forward

Neuro-Oncology(2022)10.1093/neuonc/noac275
N/A
0DataRank · unranked
3 citations

Isabel Arrillaga‐Romany, Julie J. Miller

MR spectroscopic imaging predicts early response to anti-angiogenic therapy in recurrent glioblastoma

Neuro-Oncology Advances(2021)10.1093/noajnl/vdab060
N/A
0DataRank · unranked
14 citations

Mohamed E. El-Abtah, Daniel Kim, Jörg Dietrich, Melanie Fu, Michael Wenke +16 more

Developing a Virtual Equity Hub: Adapting the Tumor Board Model for Equity in Cancer Care

The Oncologist(2022)10.1093/oncolo/oyac069
N/A
0DataRank · unranked
18 citations

Naomi Y. Ko, Elizabeth Paige Walsh, Veronica Decker, Isabel Arrillaga‐Romany, Scott R. Plotkin +4 more

Single-agent ONC201 in recurrent H3 K27M-mutant diffuse midline glioma.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.3615
N/A
0DataRank · unranked
2 citations

Sylvia C. Kurz, Rohinton S. Tarapore, Ashley Sumrall, Nicholas Butowski, Rebecca A. Harrison +15 more